2927
AFC-Hd Amus Life Sciences Co., Ltd.
2026/07/15
For the third quarter of the fiscal year ending August 2026, revenue was approximately JPY 2.53 billion, a 2.2% increase YoY. Strong performance in pharmaceutical and healthcare businesses led to sustained revenue growth, while total net income was JPY 117 million, a decrease of 82.6% YoY.
